5月30日,人工甜味剂生产商新琪安启动港股IPO招股,计划发行1058.54万股H股,其中香港公开发售占10%。招股价区间为18.9-20.9港元,每手200股入场费约4222.16港元,预计6月10日挂牌,民银资本担任独家保荐人。
该公司主营食品级甘氨酸及三氯蔗糖生产,按2023年销量及销售额统计,其食品级甘氨酸全球市场份额达5.1%和3.1%,位居行业首位。2024年财报显示,年度收益5.7亿元(人民币,下同),同比增长27.3%;净利润4340.6万元,同比微降2.8%。
据悉,本次IPO引入Reynold Lemkins和合赢两家基石投资者,合计认购6000万港元。募集资金约21.3%将用于泰国工厂的异麦芽酮糖醇生产及三氯蔗糖扩产,55.3%投向海藻膳食纤维及丝氨酸项目。目前该公司产品覆盖全球六大洲40个国家。
公开资料显示,新琪安三氯蔗糖业务在全球市场份额约4.8%,位列行业前五。此次上市募资剩余13.4%资金将用于研发能力提升,10%用作营运资金。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.